{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T23:40:11Z","timestamp":1792539611006,"version":"4.5.0"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T00:00:00Z","timestamp":1784592000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T00:00:00Z","timestamp":1792540800000},"content-version":"vor","delay-in-days":92,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Stichting BeterKeten"},{"name":"Stichting Onderzoek Franciscus"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-026-60981-1","type":"journal-article","created":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T05:15:11Z","timestamp":1784610911000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Epicardial adipose tissue thickness is associated with circulating biomarkers in individuals without known cardiac disease across a broad adiposity spectrum"],"prefix":"10.1038","volume":"16","author":[{"given":"J. F.","family":"Chin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Abou Kamar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P. A.","family":"Motiram","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S. M.","family":"Snelder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I.","family":"Kardys","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. J.","family":"Brugts","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R. A.","family":"de Boer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B. M.","family":"van Dalen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,21]]},"reference":[{"issue":"9","key":"60981_CR1","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1038\/s41569-022-00679-9","volume":"19","author":"G Iacobellis","year":"2022","unstructured":"Iacobellis, G. Epicardial adipose tissue in contemporary cardiology. Nat. Rev. Cardiol. 19 (9), 593\u2013606 (2022).","journal-title":"Nat. Rev. Cardiol."},{"issue":"20","key":"60981_CR2","doi-asserted-by":"publisher","first-page":"2360","DOI":"10.1016\/j.jacc.2018.03.509","volume":"71","author":"M Packer","year":"2018","unstructured":"Packer, M. Epicardial adipose tissue may mediate deleterious effects of obesity and inflammation on the myocardium. J. Am. Coll. Cardiol. 71 (20), 2360\u20132372 (2018).","journal-title":"J. Am. Coll. Cardiol."},{"issue":"6","key":"60981_CR3","doi-asserted-by":"publisher","first-page":"860","DOI":"10.1093\/cvr\/cvaf056","volume":"121","author":"C Janssen-Telders","year":"2025","unstructured":"Janssen-Telders, C., Eringa, E. C., de Groot, J. R., de Man, F. S. & Handoko, M. L. The role of epicardial adipose tissue remodelling in heart failure with preserved ejection fraction. Cardiovasc. Res. 121 (6), 860\u2013870 (2025).","journal-title":"Cardiovasc. Res."},{"issue":"12","key":"60981_CR4","doi-asserted-by":"publisher","first-page":"2238","DOI":"10.1002\/ejhf.2741","volume":"24","author":"G van Woerden","year":"2022","unstructured":"van Woerden, G. et al. Connecting epicardial adipose tissue and heart failure with preserved ejection fraction: mechanisms, management and modern perspectives. Eur. J. Heart Fail. 24 (12), 2238\u20132250 (2022).","journal-title":"Eur. J. Heart Fail."},{"issue":"3","key":"60981_CR5","doi-asserted-by":"publisher","first-page":"e009238","DOI":"10.1161\/CIRCHEARTFAILURE.121.009238","volume":"15","author":"G van Woerden","year":"2022","unstructured":"van Woerden, G. et al. Epicardial adipose tissue and outcome in heart failure with mid-range and preserved ejection fraction. Circ. Heart Fail. 15 (3), e009238 (2022).","journal-title":"Circ. Heart Fail."},{"issue":"12","key":"60981_CR6","doi-asserted-by":"publisher","first-page":"2251","DOI":"10.1002\/ejhf.2709","volume":"24","author":"A Venkateshvaran","year":"2022","unstructured":"Venkateshvaran, A. et al. Association of epicardial adipose tissue with proteomics, coronary flow reserve, cardiac structure and function, and quality of life in heart failure with preserved ejection fraction: insights from the PROMIS-HFpEF study. Eur. J. Heart Fail. 24 (12), 2251\u20132260 (2022).","journal-title":"Eur. J. Heart Fail."},{"issue":"11","key":"60981_CR7","doi-asserted-by":"publisher","first-page":"1936","DOI":"10.1002\/ejhf.3011","volume":"25","author":"JF Chin","year":"2023","unstructured":"Chin, J. F. et al. Association between epicardial adipose tissue and cardiac dysfunction in subjects with severe obesity. Eur. J. Heart Fail. 25 (11), 1936\u20131943 (2023).","journal-title":"Eur. J. Heart Fail."},{"issue":"8","key":"60981_CR8","doi-asserted-by":"publisher","first-page":"1346","DOI":"10.1002\/ejhf.2513","volume":"24","author":"X Jin","year":"2022","unstructured":"Jin, X. et al. Epicardial adipose tissue related to left atrial and ventricular function in heart failure with preserved versus reduced and mildly reduced ejection fraction. Eur. J. Heart Fail. 24 (8), 1346\u20131356 (2022).","journal-title":"Eur. J. Heart Fail."},{"issue":"1","key":"60981_CR9","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1002\/oby.23303","volume":"30","author":"NA Yousri","year":"2022","unstructured":"Yousri, N. A. et al. Proteome-wide associations with short- and long-term weight loss and regain after Roux-en-Y gastric bypass surgery. Obes. (Silver Spring). 30 (1), 129\u2013141 (2022).","journal-title":"Obes. (Silver Spring)"},{"issue":"12","key":"60981_CR10","doi-asserted-by":"publisher","first-page":"e025585","DOI":"10.1136\/bmjopen-2018-025585","volume":"8","author":"SM Snelder","year":"2018","unstructured":"Snelder, S. M. et al. Cross-sectional and prospective follow-up study to detect early signs of cardiac dysfunction in obesity: protocol of the CARDIOBESE study. BMJ Open. 8 (12), e025585 (2018).","journal-title":"BMJ Open."},{"key":"60981_CR11","unstructured":"Olink Proteomics, A. B. Introduction to bridging Olink\u00ae NPX datasets 2025. https:\/\/cran.r-project.org\/web\/packages\/OlinkAnalyze\/vignettes\/bridging_introduction.html"},{"issue":"3","key":"60981_CR12","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1093\/ehjci\/jev014","volume":"16","author":"RM Lang","year":"2015","unstructured":"Lang, R. M. et al. Recommendations for cardiac chamber quantification by echocardiography in adults: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. Eur. Heart J. Cardiovasc. Imaging. 16 (3), 233\u2013270 (2015).","journal-title":"Eur. Heart J. Cardiovasc. Imaging"},{"issue":"7","key":"60981_CR13","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1016\/j.echo.2025.03.011","volume":"38","author":"SF Nagueh","year":"2025","unstructured":"Nagueh, S. F. et al. Recommendations for the evaluation of left ventricular diastolic function by echocardiography and for heart failure with preserved ejection fraction diagnosis: An update from the American Society of Echocardiography. J. Am. Soc. Echocardiogr. 38 (7), 537\u2013569 (2025).","journal-title":"J. Am. Soc. Echocardiogr"},{"issue":"12","key":"60981_CR14","doi-asserted-by":"publisher","first-page":"1311","DOI":"10.1016\/j.echo.2009.10.013","volume":"22","author":"G Iacobellis","year":"2009","unstructured":"Iacobellis, G. & Willens, H. J. Echocardiographic epicardial fat: a review of research and clinical applications. J. Am. Soc. Echocardiogr. 22 (12), 1311\u20131319 (2009). quiz 417\u20138.","journal-title":"J. Am. Soc. Echocardiogr"},{"issue":"1","key":"60981_CR15","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1093\/ehjci\/jeu184","volume":"16","author":"JU Voigt","year":"2015","unstructured":"Voigt, J. U. et al. Definitions for a common standard for 2D speckle tracking echocardiography: consensus document of the EACVI\/ASE\/Industry Task Force to standardize deformation imaging. Eur. Heart J. Cardiovasc. Imaging. 16 (1), 1\u201311 (2015).","journal-title":"Eur. Heart J. Cardiovasc. Imaging"},{"issue":"1","key":"60981_CR16","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1186\/s12916-023-02836-4","volume":"21","author":"M Choy","year":"2023","unstructured":"Choy, M. et al. Association between epicardial adipose tissue and incident heart failure mediating by alteration of natriuretic peptide and myocardial strain. BMC Med. 21 (1), 117 (2023).","journal-title":"BMC Med."},{"issue":"Suppl 3","key":"60981_CR17","first-page":"23","volume":"8","author":"M Furuhashi","year":"2014","unstructured":"Furuhashi, M., Saitoh, S., Shimamoto, K. & Miura, T. Fatty acid-binding protein 4 (FABP4): Pathophysiological insights and potent clinical biomarker of metabolic and cardiovascular diseases. Clin. Med. Insights Cardiol. 8 (Suppl 3), 23\u201333 (2014).","journal-title":"Clin. Med. Insights Cardiol."},{"issue":"22","key":"60981_CR18","doi-asserted-by":"publisher","first-page":"8683","DOI":"10.1021\/bi00448a003","volume":"28","author":"CA Baxa","year":"1989","unstructured":"Baxa, C. A. et al. Human adipocyte lipid-binding protein: purification of the protein and cloning of its complementary DNA. Biochemistry 28 (22), 8683\u20138690 (1989).","journal-title":"Biochemistry"},{"issue":"1","key":"60981_CR19","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1038\/s41413-022-00211-2","volume":"10","author":"D Guo","year":"2022","unstructured":"Guo, D. et al. FABP4 secreted by M1-polarized macrophages promotes synovitis and angiogenesis to exacerbate rheumatoid arthritis. Bone Res. 10 (1), 45 (2022).","journal-title":"Bone Res."},{"key":"60981_CR20","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1186\/s12933-014-0126-7","volume":"13","author":"T Fuseya","year":"2014","unstructured":"Fuseya, T. et al. Elevation of circulating fatty acid-binding protein 4 is independently associated with left ventricular diastolic dysfunction in a general population. Cardiovasc. Diabetol. 13, 126 (2014).","journal-title":"Cardiovasc. Diabetol."},{"issue":"3","key":"60981_CR21","doi-asserted-by":"publisher","first-page":"216","DOI":"10.5551\/jat.48710","volume":"26","author":"M Furuhashi","year":"2019","unstructured":"Furuhashi, M. Fatty acid-binding protein 4 in cardiovascular and metabolic diseases. J. Atheroscler Thromb. 26 (3), 216\u2013232 (2019).","journal-title":"J. Atheroscler Thromb."},{"issue":"4","key":"60981_CR22","doi-asserted-by":"publisher","first-page":"1121","DOI":"10.1253\/circj.CJ-17-1295","volume":"82","author":"M Furuhashi","year":"2018","unstructured":"Furuhashi, M. et al. Circulating fatty acid-binding protein 4 concentration predicts the progression of carotid atherosclerosis in a general population without medication. Circ. J. 82 (4), 1121\u20131129 (2018).","journal-title":"Circ. J."},{"issue":"2","key":"60981_CR23","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1042\/CS20120004","volume":"124","author":"M Liu","year":"2013","unstructured":"Liu, M. et al. Circulating adipocyte fatty acid-binding protein levels are independently associated with heart failure. Clin. Sci. (Lond). 124 (2), 115\u2013122 (2013).","journal-title":"Clin. Sci. (Lond)"},{"issue":"12","key":"60981_CR24","doi-asserted-by":"publisher","first-page":"1537","DOI":"10.1161\/CIRCULATIONAHA.106.647503","volume":"115","author":"A Xu","year":"2007","unstructured":"Xu, A. et al. Circulating adipocyte-fatty acid binding protein levels predict the development of the metabolic syndrome: a 5-year prospective study. Circulation 115 (12), 1537\u20131543 (2007).","journal-title":"Circulation"},{"issue":"3","key":"60981_CR25","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1373\/clinchem.2005.062463","volume":"52","author":"A Xu","year":"2006","unstructured":"Xu, A. et al. Adipocyte fatty acid-binding protein is a plasma biomarker closely associated with obesity and metabolic syndrome. Clin. Chem. 52 (3), 405\u2013413 (2006).","journal-title":"Clin. Chem."},{"issue":"5","key":"60981_CR26","doi-asserted-by":"publisher","first-page":"187","DOI":"10.3109\/08977194.2011.607137","volume":"29","author":"SN Breit","year":"2011","unstructured":"Breit, S. N. et al. The TGF-beta superfamily cytokine, MIC-1\/GDF15: a pleotrophic cytokine with roles in inflammation, cancer and metabolism. Growth Factors. 29 (5), 187\u2013195 (2011).","journal-title":"Growth Factors"},{"issue":"3","key":"60981_CR27","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1530\/EJE-09-0417","volume":"161","author":"I Dostalova","year":"2009","unstructured":"Dostalova, I. et al. Increased serum concentrations of macrophage inhibitory cytokine-1 in patients with obesity and type 2 diabetes mellitus: the influence of very low calorie diet. Eur. J. Endocrinol. 161 (3), 397\u2013404 (2009).","journal-title":"Eur. J. Endocrinol."},{"issue":"5","key":"60981_CR28","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1530\/EJE-12-0466","volume":"167","author":"T Kempf","year":"2012","unstructured":"Kempf, T. et al. Growth differentiation factor 15 predicts future insulin resistance and impaired glucose control in obese nondiabetic individuals: results from the XENDOS trial. Eur. J. Endocrinol. 167 (5), 671\u2013678 (2012).","journal-title":"Eur. J. Endocrinol."},{"issue":"14","key":"60981_CR29","doi-asserted-by":"publisher","first-page":"1387","DOI":"10.1161\/CIRCULATIONAHA.109.928846","volume":"122","author":"IS Anand","year":"2010","unstructured":"Anand, I. S. et al. Serial measurement of growth-differentiation factor-15 in heart failure: relation to disease severity and prognosis in the Valsartan Heart Failure Trial. Circulation 122 (14), 1387\u20131395 (2010).","journal-title":"Circulation"},{"issue":"12","key":"60981_CR30","doi-asserted-by":"publisher","first-page":"1309","DOI":"10.1093\/eurjhf\/hfq151","volume":"12","author":"R Stahrenberg","year":"2010","unstructured":"Stahrenberg, R. et al. The novel biomarker growth differentiation factor 15 in heart failure with normal ejection fraction. Eur. J. Heart Fail. 12 (12), 1309\u20131316 (2010).","journal-title":"Eur. J. Heart Fail."},{"issue":"11","key":"60981_CR31","doi-asserted-by":"publisher","first-page":"1240","DOI":"10.1093\/eurjhf\/hfs116","volume":"14","author":"A Baessler","year":"2012","unstructured":"Baessler, A. et al. Growth-differentiation factor-15 improves reclassification for the diagnosis of heart failure with normal ejection fraction in morbid obesity. Eur. J. Heart Fail. 14 (11), 1240\u20131248 (2012).","journal-title":"Eur. J. Heart Fail."},{"issue":"6","key":"60981_CR32","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1016\/j.annepidem.2004.10.004","volume":"15","author":"A Mehio-Sibai","year":"2005","unstructured":"Mehio-Sibai, A., Feinleib, M., Sibai, T. A. & Armenian, H. K. A positive or a negative confounding variable? A simple teaching aid for clinicians and students. Ann. Epidemiol. 15 (6), 421\u2013423 (2005).","journal-title":"Ann. Epidemiol."},{"issue":"16","key":"60981_CR33","doi-asserted-by":"publisher","first-page":"1269","DOI":"10.1016\/j.jacc.2025.06.055","volume":"86","author":"M Packer","year":"2025","unstructured":"Packer, M. The adipokine hypothesis of heart failure with a preserved ejection fraction: A novel framework to explain pathogenesis and guide treatment. J. Am. Coll. Cardiol. 86 (16), 1269\u20131373 (2025).","journal-title":"J. Am. Coll. Cardiol."},{"issue":"12","key":"60981_CR34","doi-asserted-by":"publisher","first-page":"5606","DOI":"10.1007\/s11695-025-08417-z","volume":"35","author":"SA Fazeli","year":"2025","unstructured":"Fazeli, S. A. & Soleimani Samarkhazan, H. Metabolic memory following metabolic bariatric surgery: Mechanisms, clinical implications, and strategies for long-term success. Obes. Surg. 35 (12), 5606\u20135624 (2025).","journal-title":"Obes. Surg."},{"issue":"12","key":"60981_CR35","doi-asserted-by":"publisher","first-page":"986","DOI":"10.1016\/j.cardfail.2019.09.002","volume":"25","author":"M Packer","year":"2019","unstructured":"Packer, M. Drugs that ameliorate epicardial adipose tissue inflammation may have discordant effects in heart failure with a preserved ejection fraction as compared with a reduced ejection fraction. J. Card Fail. 25 (12), 986\u20131003 (2019).","journal-title":"J. Card Fail."},{"issue":"3","key":"60981_CR36","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1007\/s40618-021-01687-1","volume":"45","author":"G Iacobellis","year":"2022","unstructured":"Iacobellis, G. & Baroni, M. G. Cardiovascular risk reduction throughout GLP-1 receptor agonist and SGLT2 inhibitor modulation of epicardial fat. J. Endocrinol. Invest. 45 (3), 489\u2013495 (2022).","journal-title":"J. Endocrinol. Invest."},{"issue":"6","key":"60981_CR37","doi-asserted-by":"publisher","first-page":"1068","DOI":"10.1002\/oby.22798","volume":"28","author":"G Iacobellis","year":"2020","unstructured":"Iacobellis, G. & Gra-Menendez, S. Effects of dapagliflozin on epicardial fat thickness in patients with type 2 diabetes and obesity. Obes. (Silver Spring). 28 (6), 1068\u20131074 (2020).","journal-title":"Obes. (Silver Spring)"},{"issue":"8","key":"60981_CR38","doi-asserted-by":"publisher","first-page":"680","DOI":"10.1093\/eurjpc\/zwad050","volume":"30","author":"AE Malavazos","year":"2023","unstructured":"Malavazos, A. E. et al. Human epicardial adipose tissue expresses glucose-dependent insulinotropic polypeptide, glucagon, and glucagon-like peptide-1 receptors as potential targets of pleiotropic therapies. Eur. J. Prev. Cardiol. 30 (8), 680\u2013693 (2023).","journal-title":"Eur. J. Prev. Cardiol."},{"key":"60981_CR39","doi-asserted-by":"crossref","unstructured":"Masson, W., Lavalle-Cobo, A. & Nogueira, J. P. Effect of SGLT2-Iinhibitors on epicardial adipose tissue: A meta-analysis. Cells ;10(8). (2021).","DOI":"10.3390\/cells10082150"},{"key":"60981_CR40","first-page":"9032378","volume":"2021","author":"L D\u2019Marco","year":"2021","unstructured":"D\u2019Marco, L. et al. SGLT2i and GLP-1RA in cardiometabolic and renal diseases: From glycemic control to adipose tissue inflammation and senescence. J. Diabetes Res. 2021, 9032378 (2021).","journal-title":"J. Diabetes Res."},{"issue":"11","key":"60981_CR41","doi-asserted-by":"publisher","first-page":"1820","DOI":"10.1111\/bph.13481","volume":"173","author":"R El Bekay","year":"2016","unstructured":"El Bekay, R. et al. Effects of glucagon-like peptide-1 on the differentiation and metabolism of human adipocytes. Br. J. Pharmacol. 173 (11), 1820\u20131834 (2016).","journal-title":"Br. J. Pharmacol."},{"issue":"3","key":"60981_CR42","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1089\/lap.2014.0639","volume":"25","author":"HF Fuchs","year":"2015","unstructured":"Fuchs, H. F. et al. Benefits of bariatric surgery do not reach obese men. J. Laparoendosc. Adv. Surg. Tech. A. 25 (3), 196\u2013201 (2015).","journal-title":"J. Laparoendosc Adv. Surg. Tech. A"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-60981-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-60981-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-60981-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T23:15:52Z","timestamp":1792538152000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-60981-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,21]]},"references-count":42,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["60981"],"URL":"https:\/\/doi.org\/10.1038\/s41598-026-60981-1","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,21]]},"assertion":[{"value":"15 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The institution of Dr. De Boer has received research grants and\/or fees from Alnylam, AstraZeneca, Abbott, Bristol-Myers Squibb, NovoNordisk, and Roche; Dr. de Boer has had speaker engagements with and\/or received fees from and\/or served on an advisory board for Abbott, AstraZeneca, Bristol Myers Squibb, NovoNordisk, Roche, and Zoll; Dr. de Boer received travel support from Abbott and NovoNordisk. Dr. Kardys received travel reimbursement from Olink and SomaLogic. Dr Brugts reports speaker engagement with Astra Zeneca, Abbott, Bayer, Boehringer, Novartis and Vifor in the past 5 years not related to the current work. The remaining authors report no relationships that could be construed as a conflict of interest. The institution of Dr. Van Dalen received research grants from Biotronik SE & Co. KG, Boehringer Ingelheim, Pfizer, Daiichi Sankyo, Sanofi and Novo Nordisk.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"33106"}}